Association of Subclinical Liver Fibrosis With Death in Patients With Coronary Artery Disease: A Post Hoc Analysis of the ISCHEMIA Trial

Background The fibrosis‐4 index (FIB‐4) score, a noninvasive marker of subclinical liver fibrosis, has shown prognostic utility in general surgical populations. Current risk assessment models for patients with coronary artery disease undergoing percutaneous coronary intervention or coronary artery b...

Full description

Saved in:
Bibliographic Details
Main Authors: Tulio Caldonazo, Mohamed Rahouma, Sigrid Sandner, Bjorn Redfors, Lamia Harik, Markus Richter, Hristo Kirov, Torsten Doenst, Mario F. L. Gaudino
Format: Article
Language:English
Published: Wiley 2025-07-01
Series:Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Subjects:
Online Access:https://www.ahajournals.org/doi/10.1161/JAHA.124.040848
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850075167609323520
author Tulio Caldonazo
Mohamed Rahouma
Sigrid Sandner
Bjorn Redfors
Lamia Harik
Markus Richter
Hristo Kirov
Torsten Doenst
Mario F. L. Gaudino
author_facet Tulio Caldonazo
Mohamed Rahouma
Sigrid Sandner
Bjorn Redfors
Lamia Harik
Markus Richter
Hristo Kirov
Torsten Doenst
Mario F. L. Gaudino
author_sort Tulio Caldonazo
collection DOAJ
description Background The fibrosis‐4 index (FIB‐4) score, a noninvasive marker of subclinical liver fibrosis, has shown prognostic utility in general surgical populations. Current risk assessment models for patients with coronary artery disease undergoing percutaneous coronary intervention or coronary artery bypass grafting do not account for liver dysfunction apart from overt liver cirrhosis. We analyzed the distribution of the baseline FIB‐4 score and its association with all‐cause death in patients with coronary artery disease using data from the International Study of Comparative Health Effectiveness With Medical and Invasive Approaches (ISCHEMIA) trial. Methods The baseline FIB‐4 score was calculated for all ISCHEMIA randomized participants with laboratory data (platelet count, aspartate aminotransferase, and alanine aminotransferase). The primary outcome was the association between baseline FIB‐4 and all‐cause death. Secondary outcomes were cardiovascular death, heart failure, myocardial infarction, and stroke. Multivariable Cox regression was performed adjusting for key risk factors. Results The FIB‐4 score was calculated for 3735 participants. Baseline FIB‐4 score was significantly associated with an increased risk of all‐cause (hazard ratio [HR], 1.19 [95% CI, 1.07–1.32]; P=0.001) and cardiovascular death (HR, 1.19 [95% CI, 1.04–1.36]; P=0.011). This association was consistent across the overall population and within subgroups of patients treated with percutaneous coronary intervention, coronary artery bypass grafting, and medical therapy. There was no significant association regarding heart failure, myocardial infarction, and stroke. Conclusions The FIB‐4 score may be a significant predictor of death in patients with coronary artery disease. Preprocedural hepatic assessment should be considered to stratify risk in patients undergoing invasive cardiac procedures.
format Article
id doaj-art-5100c5e5c5e64097a76bc84255f20ab7
institution DOAJ
issn 2047-9980
language English
publishDate 2025-07-01
publisher Wiley
record_format Article
series Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
spelling doaj-art-5100c5e5c5e64097a76bc84255f20ab72025-08-20T02:46:24ZengWileyJournal of the American Heart Association: Cardiovascular and Cerebrovascular Disease2047-99802025-07-01141310.1161/JAHA.124.040848Association of Subclinical Liver Fibrosis With Death in Patients With Coronary Artery Disease: A Post Hoc Analysis of the ISCHEMIA TrialTulio Caldonazo0Mohamed Rahouma1Sigrid Sandner2Bjorn Redfors3Lamia Harik4Markus Richter5Hristo Kirov6Torsten Doenst7Mario F. L. Gaudino8Department of Cardiothoracic Surgery Jena University Hospital, Friedrich‐Schiller‐University Jena GermanyDepartment of Cardiothoracic Surgery Weill Cornell Medicine New York NY USADepartment of Cardiothoracic Surgery Weill Cornell Medicine New York NY USADepartment of Population Health Sciences Weill Cornell Medicine New York NY USADepartment of Cardiothoracic Surgery Weill Cornell Medicine New York NY USADepartment of Cardiothoracic Surgery Jena University Hospital, Friedrich‐Schiller‐University Jena GermanyDepartment of Cardiothoracic Surgery Jena University Hospital, Friedrich‐Schiller‐University Jena GermanyDepartment of Cardiothoracic Surgery Jena University Hospital, Friedrich‐Schiller‐University Jena GermanyDepartment of Cardiothoracic Surgery Weill Cornell Medicine New York NY USABackground The fibrosis‐4 index (FIB‐4) score, a noninvasive marker of subclinical liver fibrosis, has shown prognostic utility in general surgical populations. Current risk assessment models for patients with coronary artery disease undergoing percutaneous coronary intervention or coronary artery bypass grafting do not account for liver dysfunction apart from overt liver cirrhosis. We analyzed the distribution of the baseline FIB‐4 score and its association with all‐cause death in patients with coronary artery disease using data from the International Study of Comparative Health Effectiveness With Medical and Invasive Approaches (ISCHEMIA) trial. Methods The baseline FIB‐4 score was calculated for all ISCHEMIA randomized participants with laboratory data (platelet count, aspartate aminotransferase, and alanine aminotransferase). The primary outcome was the association between baseline FIB‐4 and all‐cause death. Secondary outcomes were cardiovascular death, heart failure, myocardial infarction, and stroke. Multivariable Cox regression was performed adjusting for key risk factors. Results The FIB‐4 score was calculated for 3735 participants. Baseline FIB‐4 score was significantly associated with an increased risk of all‐cause (hazard ratio [HR], 1.19 [95% CI, 1.07–1.32]; P=0.001) and cardiovascular death (HR, 1.19 [95% CI, 1.04–1.36]; P=0.011). This association was consistent across the overall population and within subgroups of patients treated with percutaneous coronary intervention, coronary artery bypass grafting, and medical therapy. There was no significant association regarding heart failure, myocardial infarction, and stroke. Conclusions The FIB‐4 score may be a significant predictor of death in patients with coronary artery disease. Preprocedural hepatic assessment should be considered to stratify risk in patients undergoing invasive cardiac procedures.https://www.ahajournals.org/doi/10.1161/JAHA.124.040848chronic coronary artery diseasecoronary artery bypass grafting (CABG)liver fibrosismedical therapypercutaneous coronary intervention (PCI)
spellingShingle Tulio Caldonazo
Mohamed Rahouma
Sigrid Sandner
Bjorn Redfors
Lamia Harik
Markus Richter
Hristo Kirov
Torsten Doenst
Mario F. L. Gaudino
Association of Subclinical Liver Fibrosis With Death in Patients With Coronary Artery Disease: A Post Hoc Analysis of the ISCHEMIA Trial
Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
chronic coronary artery disease
coronary artery bypass grafting (CABG)
liver fibrosis
medical therapy
percutaneous coronary intervention (PCI)
title Association of Subclinical Liver Fibrosis With Death in Patients With Coronary Artery Disease: A Post Hoc Analysis of the ISCHEMIA Trial
title_full Association of Subclinical Liver Fibrosis With Death in Patients With Coronary Artery Disease: A Post Hoc Analysis of the ISCHEMIA Trial
title_fullStr Association of Subclinical Liver Fibrosis With Death in Patients With Coronary Artery Disease: A Post Hoc Analysis of the ISCHEMIA Trial
title_full_unstemmed Association of Subclinical Liver Fibrosis With Death in Patients With Coronary Artery Disease: A Post Hoc Analysis of the ISCHEMIA Trial
title_short Association of Subclinical Liver Fibrosis With Death in Patients With Coronary Artery Disease: A Post Hoc Analysis of the ISCHEMIA Trial
title_sort association of subclinical liver fibrosis with death in patients with coronary artery disease a post hoc analysis of the ischemia trial
topic chronic coronary artery disease
coronary artery bypass grafting (CABG)
liver fibrosis
medical therapy
percutaneous coronary intervention (PCI)
url https://www.ahajournals.org/doi/10.1161/JAHA.124.040848
work_keys_str_mv AT tuliocaldonazo associationofsubclinicalliverfibrosiswithdeathinpatientswithcoronaryarterydiseaseaposthocanalysisoftheischemiatrial
AT mohamedrahouma associationofsubclinicalliverfibrosiswithdeathinpatientswithcoronaryarterydiseaseaposthocanalysisoftheischemiatrial
AT sigridsandner associationofsubclinicalliverfibrosiswithdeathinpatientswithcoronaryarterydiseaseaposthocanalysisoftheischemiatrial
AT bjornredfors associationofsubclinicalliverfibrosiswithdeathinpatientswithcoronaryarterydiseaseaposthocanalysisoftheischemiatrial
AT lamiaharik associationofsubclinicalliverfibrosiswithdeathinpatientswithcoronaryarterydiseaseaposthocanalysisoftheischemiatrial
AT markusrichter associationofsubclinicalliverfibrosiswithdeathinpatientswithcoronaryarterydiseaseaposthocanalysisoftheischemiatrial
AT hristokirov associationofsubclinicalliverfibrosiswithdeathinpatientswithcoronaryarterydiseaseaposthocanalysisoftheischemiatrial
AT torstendoenst associationofsubclinicalliverfibrosiswithdeathinpatientswithcoronaryarterydiseaseaposthocanalysisoftheischemiatrial
AT marioflgaudino associationofsubclinicalliverfibrosiswithdeathinpatientswithcoronaryarterydiseaseaposthocanalysisoftheischemiatrial